Insilico Biopharma Announces Global Clinical Collaboration to Evaluate IN10018 in Combination with Cobimetinib for Uveal Melanoma

SHANGHAI, Oct. 17, 2019 /PRNewswire/ -- Inxmed (Shanghai) Co., Ltd. (“Inxmed” or the “Company”) announced that it has recently entered into a global clinical trial collaboration with Roche (F. Hoffmann-La Roche Ltd., “Roche”). The two parties will conduct clinical studies on the combination therapy of IN10018, Inxmed’s focal adhesion kinase (FAK) inhibitor, and Cobimetinib, Roche’s small-molecule MEK inhibitor.

This study aims to evaluate the safety, tolerability, and antitumor efficacy of the combination of IN0018 and cobimetinib in patients with uveal melanoma. Under the collaboration agreement, Inxmed (Shanghai) Co., Ltd. will serve as the sponsor of this clinical trial, and Roche will provide cobimetinib required for the trial to Inxmed (Shanghai) Co., Ltd.

Dr. Richard Carvajal, Director of Experimental Therapeutics and Director of the Melanoma Service at Columbia University Medical Center, stated, “We are currently dedicated to developing new therapies for patients with uveal melanoma and other cancers. There are no effective drugs available for metastatic uveal melanoma. The combination of IN10018 and cobimetinib has a strong biological rationale, and this combined therapy has the potential to provide treatment options for melanoma patients.”

Dr. Wang Zaiqi, Founder and CEO of Inxmed, stated, “Roche’s choice of Inxmed as a partner reflects not only its confidence in the potential of IN0018, but also its recognition of our entire clinical development team and capabilities. We are highly optimistic that this combination therapy will bring new breakthroughs to the treatment of melanoma. As a biotechnology company positioned for ‘Chinese Innovation, Global Impact’ in the era of New Drug R&D 2.0, this collaboration marks another solid step forward in Inxmed’s globalization journey.”